Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients
Information source: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiac Surgery
Intervention: Heparin sodium Hipolabor (Biological); Heparin sodium APP (Biological)
Phase: Phase 3
Status: Completed
Sponsored by: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
Summary
The objective of this study is to verify, through a randomized, single-blind, multicentre,
parallel and comparative study, the effectiveness of heparin sodium of porcine origin in
patients undergoing heart surgery at that require the aid of cardiopulmonary bypass, through
the control of hemostasis during and after surgery, based on the strengths of markers of
coagulation TCA, TTPA, Anti-Xa, heparin bioavailable and loss of excessive blood (bleeding)
at the end of the surgery.
Clinical Details
Official title: Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Primary outcome: Effectiveness of heparin of porcine origin in patients undergoing cardiovascular surgery
Secondary outcome: Evaluation of the average dose and and safety of porcine heparin.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients who agree with all aspects of the study and sign the FICT;
- Patients of both sexes;
- Patients aged above 18 years;
- Patients with cardiac surgery and requiring movement; AND
- Extracorporeal.
Exclusion Criteria:
- Patients with hematological disorders that compromise the surgical changes (eg
myeloproliferative syndromes, anemia Hb <11. 0 g / dL,
- Platelets < 150,000 mm3);
- Patients with disorders of hemostasis (INR> 1. 40) (rTTPA> 1. 40);
- Patients with renal dysfunction (creatinine> 1. 50);
- Patients with deep hyperthermia;
- Liver disease (AST and ALT> 2 times that of the reference value);
- Patients with a history of allergy to heparin or protamine;
- Patients with history of heparin-induced thrombocytopenia;
- Tables infection (eg endocarditis, infection of immune human (HIV), hepatitis B and
C, septicemia and pneumonia);
- Reoperations;
- Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days;
- Use of acetylsalicylic acid is less than 5 days;
- Use of low molecular weight heparin for less than 24 hours; OR
- Use of non-fractioned heparin for less than 12 hours.
Locations and Contacts
LAL Clinica, Valinhos, SP 13270000, Brazil
Lal Clinica Pesquisa e Desenvolvimento Ltda, Valinhos, SP 13270-000, Brazil
Additional Information
Starting date: July 2009
Last updated: February 22, 2013
|